The ZDHHC17 antibody is a research tool designed to detect ZDHHC17. a member of the DHHC (Asp-His-His-Cys) family of palmitoyltransferases. These enzymes catalyze protein S-palmitoylation, a post-translational modification critical for regulating protein localization, stability, and function. ZDHHC17. also known as Huntingtin-interacting protein 14 (HIP14), is primarily expressed in the brain and plays a role in neuronal development, synaptic plasticity, and vesicle trafficking. It interacts with huntingtin, the protein mutated in Huntington’s disease, suggesting its involvement in neurodegenerative pathways.
Antibodies against ZDHHC17 are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its expression patterns, subcellular distribution, and interactions. Researchers employ these antibodies to explore ZDHHC17’s regulatory mechanisms in health and disease, particularly in neurological disorders and cancers. For instance, studies link ZDHHC17 dysregulation to Alzheimer’s disease, synaptic dysfunction, and tumor progression, highlighting its potential as a therapeutic target.
Commercial ZDHHC17 antibodies are typically validated for specificity using knockout cell lines or tissues to minimize cross-reactivity with other DHHC family members. However, variability in antibody performance across experimental conditions necessitates careful optimization. Recent research utilizing these antibodies has uncovered novel substrates of ZDHHC17 and clarified its role in lipid raft organization and signal transduction, advancing understanding of palmitoylation’s broader biological impact.